People living with obesity have excess circulating saturated fatty acids (SFAs), and increased risk of severe respiratory viral disease.(1,2) In patients with asthma, SFAs increased activation of nod-like receptor family-pyrin domain containing 3 (NLRP3) inflammasome(3), while NLRP3 activation is implicated in severe Influenza A virus (IAV) infection.(4) This study aimed to determine if high SFA concentrations contribute to worse respiratory viral disease outcomes in people living with obesity (n=7) compared to healthy-weight controls (n=11). Plasma fatty acids were profiled via gas chromatography and correlated with infection outcomes of Peripheral blood mononuclear cells (PBMCs). PBMCs were treated with a high-dose (2500µM) or low-dose (250µM) of palmitic acid (PA) and infected with IAV. IL-1β was measured as a marker of inflammation and IFN-⍺ for anti-viral activity. PBMCs from people living with obesity treated with the high-dose SFA and infected with IAV produced heightened IL-1β compared to healthy-weight controls [90.0pg/ml (6.7, 332.9) vs. 14.5pg/ml (5.5, 114.5); p=0.004]. A dose-dependent relationship between PA treatment and IFN-⍺ response to IAV was observed. IFN-⍺ production was increased in low-dose PA treatment treated PBMCs from people living with obesity [155.6pg/ml (29.9, 187.2) vs. 59.2pg/ml (4.0, 154.4); p=0.017]. High-dose PA significantly reduced IFN-⍺ response in people living with obesity compared to low-dose PA [6.9pg/ml (2.5, 14.5) vs. 155.6pg/ml (29.9, 187.2); p<0.001]. Systemic monounsaturated fatty acid (MUFA) vaccenic acid were significantly associated with increased IFN-α (r=0.621, p=0.010) and reduced IL-6 production from PBMCs in response to IAV (r=-0.550, p=0.042), while systemic polyunsaturated fatty acid (PUFA) ⍺-linolenic acid correlated with reduced IL-6 production from PBMCs in response to IAV (r=-0.557, p=0.020). Therefore, high doses of SFAs may contribute to more severe inflammation and reduce anti-viral responses to IAV in people living with obesity, exacerbating respiratory viral disease severity. Conversely, certain MUFA and PUFA may exert protective effects against IAV infection.